Cargando…

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

We assessed the utility of droplet digital PCR (ddPCR) to evaluate the potential of using circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by comparing it to serum LDH levels and RECIST scores. ddPCR was shown to be reliable in distinguishing mutant from wild type alleles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang-Hao Tsao, Simon, Weiss, Jonathan, Hudson, Christopher, Christophi, Christopher, Cebon, Jonathan, Behren, Andreas, Dobrovic, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476039/ https://www.ncbi.nlm.nih.gov/pubmed/26095797 http://dx.doi.org/10.1038/srep11198

Ejemplares similares

Characterising the phenotypic evolution of circulating tumour cells during treatment
por: Tsao, Simon Chang-Hao, et al.
Publicado: (2018)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
por: Anaka, Matthew, et al.
Publicado: (2013)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces
por: Tsao, Simon Chang-Hao, et al.
Publicado: (2016)

UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma
por: Bowman, Robert L, et al.
Publicado: (2021)

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
por: Murphy, Brandon M., et al.
Publicado: (2022)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses
por: Da Gama Duarte, Jessica, et al.
Publicado: (2021)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
por: Vachtenheim, Jiri, et al.
Publicado: (2021)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status
por: Casadonte, Rita, et al.
Publicado: (2023)

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ()
por: Vella, Laura J., et al.
Publicado: (2017)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population
por: Gutiérrez-Castañeda, Luz D., et al.
Publicado: (2020)

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma
por: Kumar, Raj, et al.
Publicado: (2019)

Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Efficacy of Targeted Radionuclide Therapy Using [(131)I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
por: Akil, Hussein, et al.
Publicado: (2021)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
por: Shackelford, Rodney, et al.
Publicado: (2014)

CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells
por: Ahmed, Rehana L., et al.
Publicado: (2019)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
por: Heppt, Markus V., et al.
Publicado: (2017)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
por: Parker, Robert, et al.
Publicado: (2015)

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
por: Jayachandran, Aparna, et al.
Publicado: (2014)

Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
por: Conway, Caroline, et al.
Publicado: (2010)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature
por: Chen, Feng, et al.
Publicado: (2018)

Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
por: Gutiérrez-Castañeda, Luz Dary, et al.
Publicado: (2020)

A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities
por: Bok, Ilah, et al.
Publicado: (2021)

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
por: Gutierrez-Prat, Nuria, et al.
Publicado: (2022)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pmma3r4kvntoci48fablqmcksp